Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 1
2014 1
2015 1
2017 1
2018 3
2021 4
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m heratsi (203 results)?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Falsey AR, et al. N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29. N Engl J Med. 2021. PMID: 34587382 Free PMC article. Clinical Trial.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Herati RS, et al. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. Nat Immunol. 2022. PMID: 35902637 Free PMC article.
Laparoendoscopic single-site pfannenstiel donor nephrectomy.
Andonian S, Herati AS, Atalla MA, Rais-Bahrami S, Richstone L, Kavoussi LR. Andonian S, et al. Urology. 2010 Jan;75(1):9-12. doi: 10.1016/j.urology.2009.08.074. Epub 2009 Nov 13. Urology. 2010. PMID: 19913888
The median age was 46 years with median body mass index of 28.3 kg/m(2). The median operative time was 142 minutes with a median warm ischemia time of 5 minutes. ...
The median age was 46 years with median body mass index of 28.3 kg/m(2). The median operative time was 142 minutes with a median warm …
SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M, Sajadi MM, Simon V. Frieman M, et al. EBioMedicine. 2021 Jun;68:103401. doi: 10.1016/j.ebiom.2021.103401. Epub 2021 May 26. EBioMedicine. 2021. PMID: 34051441 Free PMC article. No abstract available.
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection.
Ivanova EN, Shwetar J, Devlin JC, Buus TB, Gray-Gaillard S, Koide A, Cornelius A, Samanovic MI, Herrera A, Mimitou EP, Zhang C, Karmacharya T, Desvignes L, Ødum N, Smibert P, Ulrich RJ, Mulligan MJ, Koide S, Ruggles KV, Herati RS, Koralov SB. Ivanova EN, et al. iScience. 2023 Nov 24;26(12):108572. doi: 10.1016/j.isci.2023.108572. eCollection 2023 Dec 15. iScience. 2023. PMID: 38213787 Free PMC article.
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
Tada T, Zhou H, Dcosta BM, Samanovic MI, Chivukula V, Herati RS, Hubbard SR, Mulligan MJ, Landau NR. Tada T, et al. EBioMedicine. 2022 Apr;78:103944. doi: 10.1016/j.ebiom.2022.103944. EBioMedicine. 2022. PMID: 35465948 Free PMC article.
FUNDING: The work was funded by grants from the NIH to N.R.L. (DA046100, AI122390 and AI120898) and 55 to M.J.M. (UM1AI148574)....
FUNDING: The work was funded by grants from the NIH to N.R.L. (DA046100, AI122390 and AI120898) and 55 to M.J.M. (UM1AI148574) …
Patient and in-hospital predictors of post-discharge opioid utilization: Individualizing prescribing after radical prostatectomy based on the ORIOLES initiative.
Su ZT, Becker REN, Huang MM, Biles MJ, Harris KT, Koo K, Han M, Pavlovich CP, Allaf ME, Herati AS, Patel HD. Su ZT, et al. Urol Oncol. 2022 Mar;40(3):104.e9-104.e15. doi: 10.1016/j.urolonc.2021.10.007. Epub 2021 Nov 29. Urol Oncol. 2022. PMID: 34857445
The factors most strongly associated with post-discharge opioid utilization included inpatient opioid utilization in the final 12 hours before discharge (+39.6 post-discharge OMEQ if inpatient OMEQ was >15 vs. 0), maximum patient-reported pain score (range 0-10) in the 12 hour …
The factors most strongly associated with post-discharge opioid utilization included inpatient opioid utilization in the final 12 hours befo …
15 results